The global mycoplasma testing market size was valued at USD 708.26 million in 2020 and is projected to expand at a high CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the rising R&D investments and increasing cell culture contamination. Growing introduction of novel technology from key players is projected to fuel the market growth.
Request Free Sample Report Here
Many government authorities are supporting biotechnological and pharmaceutical sectors to expand their research activities The US Food and Drug Administration (FDA) in April 2019 introduced a policy to alter the regulations that were affecting testing method used in detection of mycoplasma. According to the agency, this regulation prevented use of other testing methods, which proved to be in the improvement in mycoplasma detection tests. There are more than 190 mycoplasma species identified and out of which, only eight are dominating as they occupy around 96% of cell culture contaminations. For growing number of cell culture contamination, some factors are responsible such as cross-contamination due to faulty or broken laminar flow, dust, practices and aerosols. Additionally, the research works in laboratories is badly affected by mycoplasma contamination and testing of theses bacteria is required for generation of robust data in the field of biomedical research.
Market Trends, Drivers, Restraints, and Opportunities
- Rising concerns on cell culture contamination is one of the key drivers for the mycoplasma testing market growth.
- Rising adoption of advanced technology and growing demand for accurate, affordable and fast testing are estimated to drive the market growth.
- Increasing funding from government for R&D activities and existing vast application of mycoplasma testing products are key factors boosting the market.
- Rapid growth of many biotechnological, pharmaceutical, and academic institutes and growing outsourcing functions such as clinical trial management, drug discovery to CROs, R&D, and manufacturing are creating immense opportunities for the market players.
- Restriction entry for new entrants due to high degree of consolidation results in limited investments. This is projected to hamper the growth of the market.
Mycoplasma Testing Market Segment Insights
Kits & reagents segment to account for a key share
Based on products, the global mycoplasma testing market is divided into instruments, kits & reagents, and services. The kits & reagents segment is further classified as PCR assays, nucleic acid detection kits, stains, elimination kits, standards & controls, and others. In 2019, the kits & reagents segment is estimated to account for a large market share. Continuous buying of consumables for detecting mycoplasma in cell culture research work and other applications are key factors for the kits and reagents segment growth. Within the segment, the PCR assays helps in precise mycoplasma identification and gives results within few hours.
PCR segment to hold a significant market share
On the basis of technology, the market is divided into PCR, ELISA, direct assay, and microbial culture. The PCR segment is projected to hold a significant market share during the forecast period. Using this technology, multiple species of mycoplasma are detected by separating other contaminating DNA and ensuring efficient result. Moreover, the rapid detection and ease procedure handling PCR test are major factors pushing to rise demand for the technique.
Cell line testing segment held a key share in the market
Based on applications, the global mycoplasma testing market is divided into cell line testing, virus testing, end of production cells testing, and others. The cell line testing segment accounted for a key revenue market share in 2019 and is expected to grow significantly during the forecast period due to increasing research activities in cell culture field and growing mycoplasma contamination in cell culture.
Pharmaceutical & biotechnology companies to constitute a large market share
Based on end-users, the global mycoplasma testing market is divided into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others. The pharmaceutical and biotechnology companies segment accounted for a major market share in 2019 and is anticipated to constitute a large market share in the coming years.
North America is expected to dominate the market
On the basis of regions, the global mycoplasma testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. In 2019 the market was dominated by North America and the trend is expected to continue in the coming years. Factor such as increasing investments and spending on healthcare especially from the US government to promote activities based on research in biopharmaceutical industries.
Competitive Landscape
Some of the key market players include TBionique Testing Laboratories, Inc., Lonza Group Ltd., Merck KGaA, PromoCell GmbH, ATCC (American Type Culture Collection), Biological Industries Israel Beit Haemek Ltd., Charles River Laboratories International, Inc., Thermo Fisher Scientific, and InvivoGen.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
